Klinik für Orthopädie und Orthopädische Chirurgie, Universitätskliniken des Saarlandes, Homburg/Saar, Germany.
Int J Med Sci. 2009 Sep 2;6(5):265-73. doi: 10.7150/ijms.6.265.
The aim of this retrospective study was to identify and evaluate complications after hip spacer implantation other than reinfection and/or infection persistence. Between 1999 and 2008, 88 hip spacer implantations in 82 patients have been performed. There were 43 male and 39 female patients at a mean age of 70 [43-89] years. The mean spacer implantation time was 90 [14-1460] days. The mean follow-up was 54 [7-96] months. The most common identified organisms were S. aureus and S. epidermidis. In most cases, the spacers were impregnated with 1 g gentamicin and 4 g vancomycin/80 g bone cement. The overall complication rate was 58.5% (48/82 cases). A spacer dislocation occurred in 15 cases (17%). Spacer fractures could be noticed in 9 cases (10.2%). Femoral fractures occurred in 12 cases (13.6%). After prosthesis reimplantation, 16 patients suffered from a prosthesis dislocation (23%). 2 patients (2.4%) showed allergic reactions against the intravenous antibiotic therapy. An acute renal failure occurred in 5 cases (6%). No cases of hepatic failure or ototoxicity could be observed in our collective. General complications (consisting mostly of draining sinus, pneumonia, cardiopulmonary decompensation, lower urinary tract infections) occurred in 38 patients (46.3%). Despite the retrospective study design and the limited possibility of interpreting these findings and their causes, this rate indicates that patients suffering from late hip joint infections and being treated with a two-stage protocol are prone to having complications. Orthopaedic surgeons should be aware of these complications and their treatment options and focus on the early diagnosis for prevention of further complications. Between stages, an interdisciplinary cooperation with other facilities (internal medicine, microbiologists) should be aimed for patients with several comorbidities for optimizing their general medical condition.
本回顾性研究旨在确定和评估除再感染和/或感染持续存在以外的髋关节间隔器植入后的并发症。1999 年至 2008 年间,82 例患者中进行了 88 例髋关节间隔器植入术。43 例为男性,39 例为女性,平均年龄 70[43-89]岁。平均间隔器植入时间为 90[14-1460]天。平均随访时间为 54[7-96]个月。最常见的分离菌为金黄色葡萄球菌和表皮葡萄球菌。在大多数情况下,间隔器用 1g 庆大霉素和 4g 万古霉素/80g 骨水泥浸渍。总体并发症发生率为 58.5%(48/82 例)。15 例(17%)发生间隔器脱位。9 例(10.2%)可发现间隔器骨折。12 例(13.6%)发生股骨干骨折。在假体再植入后,16 例患者发生假体脱位(23%)。2 例(2.4%)患者对静脉内抗生素治疗有过敏反应。5 例(6%)发生急性肾功能衰竭。本研究未观察到肝功能衰竭或耳毒性病例。大多数为引流窦道、肺炎、心肺失代偿、下尿路感染的一般并发症共发生在 38 例患者(46.3%)。尽管该研究为回顾性研究设计,且解释这些发现及其原因的可能性有限,但该发生率表明患有晚期髋关节感染并接受两阶段方案治疗的患者易发生并发症。矫形外科医生应了解这些并发症及其治疗选择,并专注于早期诊断以预防进一步的并发症。在两阶段之间,应针对患有多种合并症的患者与其他机构(内科、微生物学家)进行跨学科合作,以优化其一般医疗状况。